Visceral Vein Thrombosis of Myeloproliferative Neoplasm --Review.
10.19746/j.cnki.issn.1009-2137.2022.05.052
- Author:
Xia ZHANG
1
;
Jie YANG
2
;
Hong-Ling HAO
3
Author Information
1. Hebei North University, Zhangjiakou 075000, Hebei Province, China.
2. Department of Hematology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China.
3. Department of Hematology, Hebei General Hospital, Shijiazhuang 050051, Hebei Province, China,E-mail: h0707@163.com.
- Publication Type:Review
- Keywords:
JAK2V617F mutation;
myeloproliferative neoplasm;
polycythemia vera;
visceral venous thrombosis
- MeSH:
Aged;
Anticoagulants;
Female;
Humans;
Janus Kinase 2/genetics*;
Janus Kinase Inhibitors;
Mutation;
Myeloproliferative Disorders/genetics*;
Neoplasms;
Thrombosis;
Venous Thrombosis
- From:
Journal of Experimental Hematology
2022;30(5):1627-1630
- CountryChina
- Language:Chinese
-
Abstract:
Classical myeloproliferative neoplasm (MPN) related thrombosis mainly affects elderly patients and often involves arterial circulation, while, MPN-visceral venous thrombosis (SVT) mainly affects young women, and is closely associated with JAK2V617F mutation but not closely with CALR mutation. The pathogenesis of MPN-SVT is not only related to JAK2V617F mutation and vascular endothelial damage, but also needs further research to determine the machanism. JAK2V617F mutation is the most common in MPN-SVT clinically. Patients with non-cirrhotic SVT need to detect MPN mutation, while the detection of CALR or MPL mutation needs to be combined with clinical judgment. At present, the main treatment strategies of MPN-SVT are JAK inhibitors, supplementation of anticoagulants and treatment of portal hypertension. This article reviews the latest research progress on the epidemiology, pathogenesis, diagnosis and treatment strategies of MPN-SVT.
